These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23877740)

  • 1. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?
    Clark RE; Baxter JD
    JAMA Intern Med; 2013 Sep; 173(17):1571-2. PubMed ID: 23877740
    [No Abstract]   [Full Text] [Related]  

  • 2. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
    Clark RE; Samnaliev M; Baxter JD; Leung GY
    Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
    Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
    Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
    Barenie RE; Sinha MS; Kesselheim AS
    Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
    Martin PR; Finlayson AJ
    Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
    Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
    J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
    Johnson B; Richert T
    J Addict Dis; 2015; 34(1):1-17. PubMed ID: 25496247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial factors and the implementation of medications for treating opioid use disorders.
    Knudsen HK; Roman PM
    J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine charges to uninsured patients at top-ranked U.S. hospitals.
    Niforatos JD; Dorner SC; Pescatore RM; Raja AS
    Am J Emerg Med; 2019 Dec; 37(12):2253-2254. PubMed ID: 31047741
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
    Sharp A; Jones A; Sherwood J; Kutsa O; Honermann B; Millett G
    Am J Public Health; 2018 May; 108(5):642-648. PubMed ID: 29565661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.
    Knudsen HK; Lofwall MR; Walsh SL; Havens JR; Studts JL
    J Addict Med; 2018; 12(1):31-39. PubMed ID: 28914663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
    Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
    Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public policy statement on buprenorphine for opiate dependence and withdrawal.
    J Addict Dis; 2004; 23(4):116-7. PubMed ID: 15534969
    [No Abstract]   [Full Text] [Related]  

  • 16. Vermont responds to its opioid crisis.
    Simpatico TA
    Prev Med; 2015 Nov; 80():10-1. PubMed ID: 25869219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of women treated with buprenorphine during pregnancy.
    Alto WA; O'Connor AB
    Am J Obstet Gynecol; 2011 Oct; 205(4):302-8. PubMed ID: 21640969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.
    Baxter JD; Clark RE; Samnaliev M; Aweh G; O'Connell E
    Subst Abus; 2015; 36(2):174-82. PubMed ID: 25706332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.